Cardiff Oncology and Nerviano amend onvansertib licence agreement and resolve dispute
Cardiff Oncology and Nerviano have resolved their licensing dispute and amended the global onvansertib licence agreement, updating exclusivity, economics and termination provisions.
The companies have settled litigation relating to Cardiff's rights to onvansertib and revised the terms of their 2017 exclusive worldwide licence agreement without either party making a settlement payment.
The amended agreement provides a clearer commercial framework for continued development of onvansertib, Cardiff's PLK1 inhibitor being evaluated across multiple oncology indications.
Field | Content |
Alert Type | Deal |
Companies | Cardiff Oncology; Nerviano Medical Sciences |
Deal Type | Licence amendment and dispute settlement |
Asset or Company | Onvansertib |
Therapy Area(s) | Oncology |
Technology or Modality | PLK1 inhibitor; small-molecule targeted therapy |
Deal Value | No settlement payment; revised licence economics and contractual terms |
Geography | Worldwide |
What Happened | Cardiff Oncology and Nerviano resolved litigation over the global rights to onvansertib and amended their 2017 exclusive worldwide licence agreement. |
Why It Matters | The settlement removes legal uncertainty around Cardiff's principal oncology asset and establishes updated commercial and contractual terms for its continued development. |
Supporting Context | Onvansertib is an oral small-molecule inhibitor of polo-like kinase 1, or PLK1, being developed by Cardiff Oncology in multiple cancer settings. |
Strategic Rationale | The revised agreement gives both companies greater clarity around exclusivity, economics and termination rights while allowing Cardiff to continue advancing onvansertib. |
Potential Impact | Resolution of the dispute reduces a potential development and financing overhang for Cardiff's oncology pipeline. |
Key Takeaway | Cardiff Oncology and Nerviano have settled their onvansertib licensing dispute and agreed revised terms governing the global programme. |
What to Watch | Further clinical development of onvansertib and the practical impact of the revised licence economics on Cardiff's commercial strategy. |
Primary Source | Cardiff Oncology |
Relevant Date | 11 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare